PL2542241T3 - Sposoby i kompozycje do leczenia lub zapobiegania objawom wahań hormonalnych - Google Patents

Sposoby i kompozycje do leczenia lub zapobiegania objawom wahań hormonalnych

Info

Publication number
PL2542241T3
PL2542241T3 PL11751180.8T PL11751180T PL2542241T3 PL 2542241 T3 PL2542241 T3 PL 2542241T3 PL 11751180 T PL11751180 T PL 11751180T PL 2542241 T3 PL2542241 T3 PL 2542241T3
Authority
PL
Poland
Prior art keywords
compositions
treating
methods
preventing symptoms
hormonal variations
Prior art date
Application number
PL11751180.8T
Other languages
English (en)
Inventor
Jr. George E. Royster
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of PL2542241T3 publication Critical patent/PL2542241T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL11751180.8T 2010-03-02 2011-03-01 Sposoby i kompozycje do leczenia lub zapobiegania objawom wahań hormonalnych PL2542241T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30963810P 2010-03-02 2010-03-02

Publications (1)

Publication Number Publication Date
PL2542241T3 true PL2542241T3 (pl) 2016-12-30

Family

ID=44531862

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11751180.8T PL2542241T3 (pl) 2010-03-02 2011-03-01 Sposoby i kompozycje do leczenia lub zapobiegania objawom wahań hormonalnych

Country Status (12)

Country Link
US (1) US20110218213A1 (pl)
EP (1) EP2542241B1 (pl)
JP (1) JP5839362B2 (pl)
CN (1) CN102858343B (pl)
AU (3) AU2011223807B2 (pl)
BR (1) BR112012022052B1 (pl)
CA (1) CA2828041C (pl)
EA (1) EA027350B1 (pl)
ES (1) ES2574210T3 (pl)
IL (2) IL221706A (pl)
PL (1) PL2542241T3 (pl)
WO (1) WO2011109367A2 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9616123B1 (en) * 2012-03-05 2017-04-11 Robert L. Knobler Method and compound for treatment of menopausal symptoms
JP6038416B1 (ja) * 2015-04-07 2016-12-07 株式会社明治 火照り抑制剤
US11491120B2 (en) 2017-11-09 2022-11-08 The Trustees Of Columbia University In The City Of New York Pharmacological prophylactics against stress-induced affective disorders in females
WO2019094596A1 (en) 2017-11-09 2019-05-16 The Trustees Of Columbia University In The City Of New York Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders
BR112021021260A2 (pt) * 2019-04-22 2022-02-08 L Knobler Robert Tratamento não hormonal de ondas de calor
WO2021108801A2 (en) * 2019-11-15 2021-06-03 Consegna Pharma, Inc. Long acting nmda antagonists

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5321012A (en) * 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
CA2115792C (en) * 1993-03-05 2005-11-01 David J. Mayer Method for the treatment of pain
PT729353E (pt) * 1993-11-19 2002-07-31 Alkermes Inc Preparacao de microparticulas biodegradaveis contendo um agente biologicamente activo
AUPN605795A0 (en) * 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
WO2001007037A1 (en) * 1999-07-22 2001-02-01 University Of Rochester Method of treating symptoms of hormonal variation, including hot flashes
US20040002482A1 (en) * 2000-08-30 2004-01-01 Dudley Robert E. Androgen pharmaceutical composition and method for treating depression
US6569471B2 (en) * 2000-09-01 2003-05-27 Natumin Pharma Ab Method for the treatment of symptoms related to normal hormonal variations in women
US20050129783A1 (en) * 2001-04-19 2005-06-16 Mccleary Edward L. Composition and method for treatment of neurophysiological conditions and maintenance of neurophysiological health
US20040259850A1 (en) * 2001-10-31 2004-12-23 Alves Stephen E. Method for treating or preventing symptoms of hormonal variation including hot flashes
KR20050040921A (ko) * 2002-08-15 2005-05-03 와이어쓰 체온조절 기능장애 치료를 위한 5ＨＴ2ａ 수용체의 항진제
HUP0303313A2 (hu) * 2003-10-09 2005-07-28 Richter Gedeon Vegyészeti Gyár Rt. Transzdermális gyógyszerkészítmények
US7855195B2 (en) * 2003-12-02 2010-12-21 Pharmaneuroboost N.V. Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
WO2005107808A2 (en) * 2004-05-11 2005-11-17 Pfizer Products Inc. Combination of atypical antipsychotics and 5-ht1b receptor antagonists
US20070264358A1 (en) * 2004-06-04 2007-11-15 Wittlin William A Methods and Compositions for Treating Mood Disorder
US20060122127A1 (en) * 2004-11-17 2006-06-08 Cypress Bioscience, Inc. Methods for reducing the side effects associated with mirtzapine treatment
EP1898915A4 (en) * 2005-07-06 2009-01-21 Sepracor Inc COMBINATIONS OF ESZOPICLON AND ANTIDEPRESSIVE
US8604082B2 (en) * 2005-12-13 2013-12-10 Trinity Laboratories, Inc. Method to treat premature ejaculation in humans
KR20080097443A (ko) * 2006-02-03 2008-11-05 아바니르 파마슈티컬스 덱스트로메토판 및 퀴니딘을 포함하는, 우울, 불안 및 신경퇴행성 장애 치료용 약제학적 조성물
US7645750B2 (en) * 2006-12-13 2010-01-12 Yung Shin Pharmaceutical Ind. Co., Ltd. Method of treating symptoms of hormonal variations
WO2008116024A2 (en) * 2007-03-19 2008-09-25 Acadia Pharmaceuticals Inc. Combinations of 5-ht2a inverse agonists and antagonists with antipsychotics
CA2731827C (en) * 2008-07-22 2017-11-07 Menogenix, Inc. Compositions and methods for treating symptoms associated with menopause, hormonal variations and arthritis

Also Published As

Publication number Publication date
EA027350B1 (ru) 2017-07-31
IL221706A (en) 2017-08-31
CN102858343A (zh) 2013-01-02
AU2016213776B2 (en) 2018-04-12
AU2016213776A1 (en) 2016-09-01
ES2574210T3 (es) 2016-06-15
JP2013521297A (ja) 2013-06-10
EP2542241A4 (en) 2013-11-06
BR112012022052B1 (pt) 2021-06-29
CN102858343B (zh) 2015-11-25
IL253853A0 (en) 2017-09-28
US20110218213A1 (en) 2011-09-08
AU2011223807B2 (en) 2016-05-12
BR112012022052A2 (pt) 2020-07-07
AU2018205147A1 (en) 2018-08-02
WO2011109367A4 (en) 2012-02-23
EP2542241B1 (en) 2016-04-27
WO2011109367A3 (en) 2011-12-29
IL253853B (en) 2019-05-30
EA201290851A1 (ru) 2013-04-30
EP2542241A2 (en) 2013-01-09
WO2011109367A2 (en) 2011-09-09
CA2828041A1 (en) 2011-09-09
AU2011223807A1 (en) 2012-10-18
CA2828041C (en) 2018-04-17
JP5839362B2 (ja) 2016-01-06

Similar Documents

Publication Publication Date Title
EP2603202A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF TAUOPATHIES
IL225471A0 (en) Preparations and methods for the prevention and treatment of cancer
EP2542060A4 (en) COMPOSITIONS AND METHODS FOR TREATMENT AND / OR PREVENTION OF CARDIOVASCULAR DISEASES
EP2655334A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES
HK1185623A1 (zh) 用於治療血友病 的方法和組合物
EP2554175A4 (en) COMPOSITION FOR THE TREATMENT OF A DESIRED PART
EP2771030A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF PROTEINOPATHIES
IL253853A0 (en) Methods and preparations for the treatment or prevention of symptoms of hormonal changes
EP2550263A4 (en) COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE
IL225488A0 (en) Compounds and methods for the treatment of hematological malignancies
HK1166305A1 (zh) 用於治療炎症的組合物及方法
GB201302653D0 (en) Pharmaceutical compositions and methods of treatment
EP2544655A4 (en) COMPOSITIONS AND METHODS FOR TREATING SKIN
EP2575825A4 (en) COMPOSITIONS AND METHODS FOR TREATING DEPRESSION
EP2558085A4 (en) COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF CANCER
EP2590674A4 (en) COMPOSITIONS AND METHODS FOR INFLUENZA TREATMENT
EP2523553A4 (en) METHOD AND COMPOSITIONS FOR TREATING BLOOD DISORDER
HK1167101A1 (en) Compositions and methods for treatment of multiple sclerosis
ZA201303996B (en) Compositions and methods for treating amyloid plaque associated symptoms
HK1183766A1 (zh) 用於治療瘀傷的組合物和方法
EP2549867A4 (en) COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF INJURIES
HK1257401A1 (zh) 用於治療糖尿病和相關病症的方法和組合物
IL225483A0 (en) The compositions and methods for the treatment of neoplasia
EP2608794A4 (en) METHODS AND COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF OBESITY
EP2547368A4 (en) METHOD AND COMPOSITIONS FOR CANCER TREATMENT